MedTrace Logo

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

NCT05623267 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2023-08-07

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.

Conditions

  • Limited Stage Small Cell Lung Cancer

Interventions

DRUG

Sugemalimab

Recombinant anti-PD-L1 fully human monoclonal antibody

DRUG

Placebo

Placebo of Sugemalimab

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Li Zhang, MD · Sun Yat-sen University

  • Yan Huang, MD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2025-12-31
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05623267 on ClinicalTrials.gov